A CCK agonist has been demonstrated to achieve anti-obesity effects with remarkable efficacy, reducing weight and appetite signals, but also acting like a GLP-1 potentiator when used as adjunct therapy. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.